Introduction
Behçet's disease (BD) is a chronic relapsing systemic inflammatory disorder of unknown etiopathogenesis, which is mainly characterized by oral and genital ulcerations, ocular manifestations and by involvement of the gastrointestinal, cardiovascular, pulmonary, skeletal and central nervous systems (CNS). 1 In this paper, we report a patient with epileptic seizures as the sole manifestation of neurological involvement (neuro-BD), which were successfully controlled with interferon-alpha (IFN-a). Seizure (2008) Interferon-alpha Summary Behçet's disease (BD) is a multisystemic disease of unknown etiopathogenesis with various clinical features including manifestations from central nervous system involvement. We report the case of a patient presented with a 20-year history of BD and a 10-year history of epileptic seizures refractory to various antiepileptic drugs. Under systemic treatment with interferon-a 2a (IFN-a) a complete remission of the cutaneous manifestations and a seizure-free state were achieved. The impressive therapeutic response of both the seizures and the non-neurological manifestations to IFN-a was also observed upon re-administration of this cytokine subsequent to a severe BD relapse. In view of this response and the lack of any other obvious etiology of the seizures in our patient, it seems reasonable to consider them as being the sole manifestation of neuro-BD. The patient is presently completing a 40-month seizurefree follow-up, despite withdrawal of all antiepileptic drugs for the last 35 months. Further studies on large numbers of patients are now warranted to define the therapeutic efficacy and safety of IFN-a in neuro-BD and particularly in neuro-BDrelated epileptic seizures. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
In January 2001, a Greek 47-year-old man with a 20-year history of painful and recurrent oral and skin lesions was admitted to the Department of Dermatology, at the University of Patras Medical Center. According to the patient, no definite diagnosis had been made with regard to his oral and skin lesions by his hometown dermatologists, who had treated him over a period of 20 years with steroids with limited success.
Additionally, the patient had a 10-year history of generalized tonic-clonic seizures occurring during sleep (6-8 month À1 ) and complex partial type seizures occurring during daytime (4-5 month À1 ), that were characterized by impairment of consciousness, an unpleasant feeling arising from his stomach followed by involuntary swallowing movements and by optic hallucinations. He consulted several neurologists, who described an unremarkable neurological examination. In the electroencephalogram (EEG) they found paroxysmal activity consisting of short or long series of slow activity at 3-5 Hz intermixed with isolated sharp and slow wave complexes independently occurring over the left and less frequently over the right temporal area. Since brain MRI disclosed no lesions and the cerebrospinal fluid analysis and the routinely performed laboratory investigations showed no abnormalities, the patient's epilepsy was considered by his neurologists to be cryptogenic. As they stated, the therapeutic response to sodium valproate 1500 mg/day and to lamotrigine (200 mg/day), which was additionally given, was disappointing. Over the next 10 years, the patient reportedly switched to oxcarbazepine (1200 mg/day) and later to topiramate (300 mg/day) and levetiracetam (3000 mg/day) without any beneficial effect on the frequency of his seizures. However, as we were informed by his neurologists, the plasma levels of the administered antiepileptic drugs had never been monitored.
On the first admission of the patient to our Institution, physical examination revealed aphthous lesions in the oral mucosa, erythema nodosum on the extensor surface of both lower extremities, pseudofolliculitis lesions on the trunk and a positive pathergy (needle reaction) test. Since the patient fulfilled the criteria of the International Study Group for BD, the diagnosis of BD was established. 2 Apart from an increase of the erythrocyte sedimentation rate and of g-glutamyl transferase serum levels, the results of all biochemical, haematological, serological, X-ray, ultrasound, ophthalmologic, cardiologic and clinical neurological examinations were either negative or within normal limits. In particular, the autoimmune screening including antinuclear, anti-DNA, anti-single and double stranded DNA, anti-SM, anti-Ro, anti-La and lupus anticoagulant antibodies, IgG anti-cardiolipin, C3 & C4 components of the complement, rheumatoid factor, ASMA, AMA, APA, p-ANCA, c-ANCA, immunoglobulins, cryoagglutinins was unremarkable. Upon his admission and despite continuation of treatment with topiramate (300 mg/day) and levetiracetam (3000 mg/day), the patient suffered from frequent epileptic seizures.
For the therapeutic management of BD human recombinant IFN-a (Roferon; Roche Hellas, Athens, Greece) was subcutaneously administered to the patient at a dose of 6 Â 10 6 IU per day, three times per week. Symptoms of influenza-like syndrome could be prevented by oral paracetamol given to the patient 30 min prior to interferon administration. Apart from a transient depression of white-cell counts, no significant alterations of laboratory variables could be detected, as compared to the pretreatment phase. Already after 2 weeks of treatment oral aphthae completely disappeared, whereas a complete remission of erythema nodosum and pseudofolliculitis was observed by the end of the fourth and the fifth week, respectively. Additionally, under interferon therapy and the continuing antiepileptic medication, a progressive decrease in the frequency of the patient's seizures was observed and for the first time a seizure-free state was achieved 5 months after onset of IFN-a therapy.
In September 2001, the patient decided to discontinue the interferon administration but kept on taking his antiepileptic medication. He remained thereafter free of any cutaneous lesions and seizures until June 2004 when he was readmitted due to a massive relapse characterized by the occurrence of multiple aphthous lesions in the oral cavity, the cecum and the sigmoid, erythema nodosum on the lower extremities, pseudofolliculitis on the trunk, positive pathergy test and epileptic seizures. IFN-a administration (6 Â 10 6 IU per day, three times per week) was then restarted and led to a complete remission of the disease within 9 weeks. In view of the favourable response of his severe intestinal involvement and seizures to IFN-a, the patient received from June 2004 until August 2007 the same dosage of IFN-a. Since September 2007, he receives 3 Â 10 6 IU IFN-a two times per week, whereas his antiepileptic medication has been discontinued since January 2005. The patient is presently completing a 35-month antiepileptic-free follow-up and reveals no seizures or any non-neurological manifestations of BD, whereas his EEG pattern has returned to normal. IFN-a is well tolerated and no signs of depression have been found.
Discussion
Although the etiopathogenesis of BD remains to be elucidated, it is generally accepted that a severe vasculitis involving arteries and veins of all sizes is the cardinal pathological substrate of the affected tissues and organs in this disorder. 3 Viral and bacterial antigens are thought to be implicated in the development and maintenance of this vasculitis in genetically predisposed individuals.
Neurological involvement in BD varies from 2.5 to 49% of cases and represents one of the most severe BD manifestations. Two distinct patterns of CNS involvement have been recognized, parenchymal and non-parenchymal or neuro-vascular. 1, 4 Data on the occurrence of epileptic seizures as evidence of parenchymal CNS involvement in BD are very sparse. The reported frequency of the seizures greatly varies (0-27%), probably depending on ethnicity and environmental factors. 4, 5 Epileptic seizures may occur during either the exacerbations or the chronic course of BD as simple or complex partial seizures, myoclonic jerks and generalized tonicclonic seizures. [5] [6] [7] To our knowledge, there is only one clearly documented report of neuro-BD presenting with seizures, 6 followed later by other CNS manifestations.
The case presented here could be regarded as rather atypical for neuro-BD and a mere casual coexistence of epilepsy and BD should be taken into consideration. However, this possibility seems very unlikely in view of: (1) the absence of any obvious etiology despite vigorous investigations over a 10-year period and (2) the impressive therapeutic response of both, the seizures and the non-neurological manifestations of BD in our patient not only to the initial IFN-a course of treatment but also to its re-administration (subsequent to BD relapse) and the 40-month seizure-free follow-up, despite withdrawal of all antiepileptic drugs for the last 35 months. It seems reasonable, therefore, to consider the epileptic seizures of our patient as being the sole manifestation of CNS involvement in BD (neuro-BD). In the majority of cases with neuro-BD-related epileptic seizures, EEG shows non-specific slow activity and only rarely distinct focal abnormalities are seen. Brain MRI often discloses single or scattered focal lesions suggestive of CNS vasculitis. 1, 6, 7 The EEG findings in our case confirmed the diagnosis of epilepsy and implied the presence of a focal temporal dysfunction. In view of the low sensitivity of MRI in detecting cerebral dysfunction, 8 the absence of structural lesions on brain MRI, as in our case, does not exclude the diagnosis of neuro-BD. In a retrospective study Aykutlu et al. 5 reported that treatment with conventional antiepileptics was capable of controlling the seizures in most evaluated patients with neuro-BD. The striking therapeutic failure of first choice antiepileptic drugs observed in our patient keeps up with the findings of Aktekin et al. 7 in a severe case of neuro-BD, in which these compounds caused a reduction in the frequency but not a complete cessation of seizures.
Tsambaos et al. 9 were the first to introduce the systemic application of IFN-a in the treatment of BD. The impressive therapeutic results observed by these authors were confirmed in a large number of subsequent clinical trials. Thus, IFN-a is presently regarded as a highly effective, safe and well tolerated form of therapy for the mucocutaneous, articular and ocular manifestations of BD. 10, 11 To our knowledge, the efficacy of this cytokine in the management of neuro-BD-related epileptic seizures has never been studied. Nichols et al. 12 reported resolution of generalized tonic-clonic seizures in a patient with neuro-BD and attributed it to IFN-a treatment. Nevertheless, the concomitant administration of colchicine to their patient, a compound with well-known therapeutic effects on BD, hampered the assessment of the therapeutic efficacy of IFN-a alone. It is obvious that, due to the spontaneous exacerbations and remissions marking the clinical course of BD, the evaluation of various therapeutic regimens is difficult. However, the presented case shows, for the first time, that IFN-a was capable of completely controlling neuro-BD-related epileptic seizures. The mechanisms underlying the therapeutic action of IFN-a on the seizures of our patient remain unclear. It is possible, however, that IFN-a, apart from its immunomodulatory action on the molecular and cellular components of BDrelated vasculitis, may exert a direct effect on neural tissue.
In the presented case epilepsy was considered as refractory since our patient had failed to respond to more than three drugs and experienced more than 3-4 seizures per month. 13 One could argue that the limited therapeutic response of the epilepsy of our patient may be associated with a possibly limited bioavailability of the administered antiepileptic drugs. Unfortunately, for unknown reasons, the plasma levels of the latter were not determined during the 10-year treatment of the patient by his hometown neurologists. Upon his admission to our Institution the patient has been receiving levetiracetam (3000 mg/day) and topiramate (300 mg/ day), the plasma levels of which were not determined because their monitoring is of limited clinical value. Furthermore, a clinically relevant interaction of these antiepileptic agents with IFN-a, which could have caused alterations of their plasma levels, is almost impossible for the following reasons:
1. Levetiracetam shows limited metabolism and has no potential to produce clinically relevant pharmacokinetic drug interactions through inhibition or induction of liver CYP450 enzymes. 14 On the other hand, it undergoes minimal metabolism (<2.5%) by CYP450 enzymes which is not altered by known CYP450 inducers and inhibitors. 15 2. IFN-a is known to be capable of inducing CYP1A, CYP2C19, CYP2D6 and CYP2E1. 16 None of these enzymes catalyzes the metabolism of Topiramate, which is metabolized by CYP3A4. The latter is induced by its substrate. 17 Further studies on large numbers of patients are now warranted to define the therapeutic efficacy and safety of IFN-a in neuro-BD and particularly in neuro-BD-related epileptic seizures.
